Nat. Volatiles & Essent.

Oils, 2021; 8(6): 1558-1565

History, Current Status And Future Aspects Of

pharmacovigilance In India
Kajal Pansare1*, Ganesh Sonawane1 , Prashant Tapadiya2 , Renu Tapadiya3 , Chandrashekhar
Patil4,5 , Jai Singh Vaghela5 , Shekhar Kokate1

1
Assistant Professor, SND College of Pharmacy, Yeola, Maharashtra (India)
2
Senior Project Manager, Clinical Development Department, Alvogen Pharma (India)
3
Lecturer, Bhalchandra College of Pharmacy, Pune, Maharashtra (India)
4
Assistant Professor, Divine College of Pharmacy, Satana, Maharashtra (India)
5
Bhupal Nobel University, Udaipur, Rajasthan (India)

ABSTRACT

Pharmacovigilance(PV) is defined by the World Health Organization (WHO) as "the research and practices
associated to the detection, evaluation, comprehension, and prevention of adverse effects or other important
issues caused by drugs."Pharmacovigilance is primarily concerned with the detection of Adverse drug reactions
(ADRs) of drugs.Safety of medications is one of the important factors for success of any therapy, along with
therapeutic efficacy, in the ever-increasing range and potency of medicines. India is currently a desirable clinical
testing locationfor to be launched drug entities.The PV activity is regulated in India by the Indian Pharmacopoeia
Commission (IPC) and the National Coordination Committee (NCC) through the Central Drug Standard Control
Organization (CDSCO). The Indian government planned and launched the Pharmacovigilance Programme of India in
2010 to establish a potential PV system in India.To enhance regulatory compliance, clinical trial safety, and post-
marketing surveillance, the Drugs Controller General of India (DCGI) should act fast to improve PV by implementing
Good Pharmacovigilance Practice (GPP) into processes and procedures. If medicines are to be used safely, a well-
functioning PV system is essential.This article summarized introduction, history, current status and future aspects
of Pharmacovigilance in India.

Keywords:Pharmacovigilance, Adverse drug reaction, Safety, India, Uppsala monitoring center

1558
Nat. Volatiles & Essent. Oils, 2021; 8(6): 1558-1565

INTRODUCTION
Pharmacovigilanceis defined by the World Health Organization as "the research and practices associated
to the detection, evaluation, comprehension, and prevention of adverse effects or other important
issues caused by drugs(1)."Pharmacovigilance is primarily concerned with the detection of Adverse drug
reactions of drugs. ADRs are defined as "an unpleasant and unintended response to drugs that occurs at
levels normally used for disease prevention, diagnosis and therapy or for the alteration of physiological
function." PV is an essential component of clinical trials and medication development(2).Throughout the
lifecycle of a product, both clinical trial safety and post-market pharmacovigilance are essential.
Pharmacovigilance's main goal is to improve the safe and effective utilization of health products, in part
by making information readily available to patients, medical professionals, and the general public. It is
critical to detect any side effects of drugs as soon as possible, and data collection is vital(3).During the
post-marketing phase of an approved drug, spontaneous adverse drug reaction reporting (SADR) is used
to examine and monitor the risk-benefit profile of new pharmaceuticals.The field of Pharmacovigilance
deals with reports that raise concerns about the post-marketing safety of drugs that cause adverse drug
reactions(4).PV plays a vital part in the evaluation of medication side effects, whether they are induced
by oral, parenteral, or intravenous medicines. These medications are tested for adverse drug
reactionsbefore they are released globally(5).Pharmacovigilance has expanded its scope throughout
time to encompass the monitoring of herbal, traditional and complementary medicines, blood products,
medical devices, biological and vaccines, with the purpose of providing patients with the most current
information on product risks. Clinical studies now give major pharmaceutical companies with an early
warning of risks associated with their products. This kind of signal identification and risk management
has added a new dimension to the field of Pharmacovigilance, which is still expanding(6).The drug
development process includes the continuum from the identification of a potential pharmaceutical
agent to research on possible efficacy and safety through regulatory approval. The drug approval
process mainly involves phase I, II, III (pre-marketing), IV (post-marketing) trials. The National
Pharmacovigilance Program was inaugurated in November 2004 by the Central Drugs Standard Control
Organization of India's Ministry of Health and Family Welfare. It is largely based on the WHO report
"Safety Monitoring of Medicinal Products Guidelines for Establishing and Operating a Pharmacovigilance
Center(7)".With the goal of improving public safety and welfare in India, on 14 July 2010, the Indian
government launched the Pharmacovigilance Programme of India (PvPI) with the National Coordination
Center at All India Institute of Medical Sciences (AIIMS) in New Delhi, which was later transferred to the
Indian Pharmacopoeia Commission in Ghaziabad, India, in April 2011 to monitor adverse drug reactions
in the country and protect public health(8).

HISTORY
On January 29, 1848, a little girl from the north of England (Hannah Greener) died after receiving
chloroform anesthesia before to the removal of an infected toenail, marking the beginning of
pharmacovigilance(9).The second major issue arose later, and it was caused by acetylsalicylic acid. On
August 12th, 1897, Felix Hoffman, a German chemist working for Bayer, created acetylsalicylic acid,
which was better tolerated than sodium salicylate when consumed, and was given the name
Aspirin(10).The issue that arose in 1898 was the commercialization of diacetylmorphine, later known as

1559
Nat. Volatiles & Essent. Oils, 2021; 8(6): 1558-1565

heroin, which became addicted around the turn of the century. Approximately0.5 million dependent
patients were identified in the United States alone. Thalidomide was first sold as an over-the-counter
hypnotic/sedative drug in 1957, and it was later used to relieve nausea in pregnant women. This was
confirmed the following year, when it was shown that thalidomide was responsible for 20% of the
increase in phocomelia and limb agenesis of limb defects(11).The Indian government has changed and
amended Schedule Y of the Drug and Cosmetics Rules of 1945, realizing the promise of clinical research
for new therapies. Schedule Y establishes a set of clinical trial guidelines and requirements. The Indian
Council of Medical Research (ICMR) released the Ethical Standards for Biomedical Research on Human
Subjects in 2000, while the CDSCO issued the Indian Good Clinical Practice (GCP) guidelines in
2001(12).When a formal ADR monitoring system with 12 centers was planned in 1986, there was no
development or special attention paid to PV activity. In 1997, India actively participated in the WHO's
ADR Monitoring Program, which was held in Uppsala, Sweden(13).India has a population of
approximately 1.21 billion people, making it the world's second most populous country, according to the
2011 census. The pharmaceutical industry in India is worth 18 billion dollars, and it is expected to
develop at a rate of 12-14 % per year. India is being recognized as a growing country for clinical trials,
medication discovery, research, and development on a global scale. The most critical step in preventing
or minimizing ADRs is for healthcare professionals to report them right away.In India, the ADR reporting
rate is less than 1%, compared to a global rate of 5%. One of the explanations for the lower rate in India
could be because Indian healthcare workers are more aware of Pharmacovigilance and ADR
monitoring(14).Over 65 countries had their own pharmacovigilance facilities in 2002. The WHO
Collaborating Center for Worldwide Drug Monitoring, often known as the Uppsala Monitoring Center,
coordinates WHO membership for international drug monitoring (UMC). Pharmacovigilance is now
firmly based on good scientific principles and is an important part of effective therapeutic approach.To
satisfy the public's expectations and the challenges of current public health, the field must evolve
further. A resolution was adopted at the Sixteenth World Health Assembly(15).

Table 1. The development of pharmacovigilance over time, with a focus on India(16)

Developments Year
James Lind conducted the first documented clinical research establishing the 1747
effectiveness of lemon juice in scurvy prevention.
More than 100 children have died as a result of sulfanilamide poisoning. 1937
Chloramphenicol poisoning has been associated to aplasticanemia. 1950
Toxicity to thalidomide has caused a worldwide tragedy. 1961
The 16th World Health Assembly recognizes the importance of quick action on 1963
adverse drug reactions (ADRs).
The WHO is conducting research for international drug surveillance on a small 1968
scale.
In India, clinical trials at the global standard level have started. 1996
India has joined the Adverse Drug Reaction Monitoring Program of the World 1997
Health Organization.
Pharmacovigilance is started in India. 1998

1560
Nat. Volatiles & Essent. Oils, 2021; 8(6): 1558-1565

In India, the 67th National Pharmacovigilance Center was formed 2002

The National Pharmacovigilance Program was established in India. 2004-05
Structured clinical trials have been completed in India. 2005
PvPI (Pharmacovigilance Program) has started. 2009-10

The National Pharmacovigilance Advisory Committee was established in January 2005 to supervise the
National Pharmacovigilance Program. It is based at the Central Drugs Standard Control Organization in
New Delhi.Data was collected from around the country and relayed to the Committee and the Uppsala
monitoring center in Sweden by the South-West zonal centerand the North-East zonal center.The
Mumbai center would report to three regional centers, while the New Delhi center would report to two.
Each regional center would be responsible for a number of peripheral centers. There are currently 26
peripheral centers(17).In July 2010, the Ministry of Health and Family Welfare, Government of India,
launched a national pharmacovigilance programme, with the All-India Institute of Medical Sciences, New
Delhi, serving as the National Coordinating Center for monitoring adverse drug reactions in the country
to protect global health.In 2010, 22 ADR monitoring centers (AMCs) were established as part of this
programmes, including AIIMS in New Delhi. In April 2011, the National Coordination Center was
relocated from New Delhi's All India Institute of Medical Science to the Indian Pharmacopoeia
Commission in Gaziabad, Uttar Pradesh, to ensuring that this initiative is implemented more
successfully(2).

PRESENT STATUS
In India, which is a vast country, there are over 6,000 licensed medicine manufacturers and over 60,000
branded formulations.India is the world's fourth largest pharmaceutical producer and is increasingly
becoming a center for clinical trials. However, in the recent history the time between when a drug is
approved for sale and when it becomes available in India has shrunk to the point that longer-term safety
data is no longer available. Additionally, through their own research efforts, Indian pharmaceutical
companies have improved their ability to develop and commercialize new products, highlighting the
importance of establishing acceptable internal pharmacovigilance standards to detect adverse drug
events(18).The Drugs Technical Advisory Board (DTAB) had previously proposed that pharmaceutical
companies be required to report adverse effects of marketed drugs. Despite the proactive nature of the
recommendations, the mandate legislation also was established in March 2016.Since many
pharmaceutical companies regard reporting ADRs to be an industry practice, periodic communications
and interactive conversations between PvPI and its stakeholders have resulted in progress in receiving
ADR reports. As a result, the pharmaceutical industry's ADR reporting rate to PvPI in 2015 was 18.80
percent(13).To promote a more effective implementation of the programme, the NCC was moved from
the AIIMS in New Delhi to the Indian Pharmacopoeia Commissionin Ghaziabad, Uttar Pradesh, on April
15th, 2011.The NCC's main goal at IPC is to create independent data on medicine safety that is
comparable to worldwide drug safety monitoring standards.PvPI's year-by-year target phases are
depicted in Table 2.

Table 2. Targets for the Pharmacovigilance Program in India (13)

1561
Nat. Volatiles & Essent. Oils, 2021; 8(6): 1558-1565

Each Financial year target for the five phases of PvPI

2010-11 Developing system and procedure
Enroll forty medical institute
Start data collection from AEFI
Establishing a training center
PV Human Resource Training
Linkage with UMC Sweden and the World Health Organization
Started developing software for the NDSD.
Zonal workshop for drug safety public awareness
News-letter publication of drug safety
2011-12 Enroll again sixty medical college
Training of PV human resource
Identify gaps and fulfill them with adequate training.
UMC, WHO provide training on PV software supply.
Software development and validation
Zonal workshop of drug safety public awareness
The publication of a drug safety bulletin

2012-13 Enroll additional hundred medical institute

PV human resource training
On a zonal basis, workshops on drug safety for the general public are held.
News-letter publication of drug safety
2013-14 Enroll again more hundred medical college
Interaction with international PV bodies
PV human resource training
The publication of a drug safety bulletin
2014-15 Create a PV center of excellence in the Pacific.

Pharmaceutical companies are required by Good Pharmacovigilance Practices (GPPs) and applicable
regulations to continuously assess the benefits and risks of their medications. Throughout the year, the
NCC-PvPI is actively involved in offering training to established pharmacovigilance professionals, on the
fundamentals and regulatory aspects of pharmacovigilance, as well as young pharmacy, medical, and
paramedical professionals. The NCC-PvPI IPC in Ghaziabad was also recognized a WHO Collaborating
Center for Pharmacovigilance in Public Health Programs and Regulatory Services on October 30th,
2017(19).The Materiovigilance Programme(MvPI) of India was established by the PvPIin 2015 to
evaluate adverse incidences associated with medical devices in India. MvPI members recently gathered
at the IPC in May 2017 to discuss strategies for monitoring the ambitious program's success.It was
determined that experienced biomedical engineers would be hired, and PvPI would provide them with
the necessary training(20).

1562
Nat. Volatiles & Essent. Oils, 2021; 8(6): 1558-1565

FUTURE ASPECT
A strong pharmacovigilance system capable of detecting novel ADRs and implementing regulatory steps
to protect public health is needed in the future. The creation of data that can assist a healthcare
practitioner or a patient in making a decision has received little attention. Pharmacovigilance's primary
purpose is to collect and communicate this information. It is vital to have information on the safety of
drug active surveillance(21).In addition to more traditional groups such as health professionals, PV will
have to focus on patients as a source of information in the future.To enhance regulatory compliance,
clinical trial safety, and post-marketing surveillance, the DCGI should act fast to improve PV by
implementing Good Pharmacovigilance Practice (GPP) into processes and procedures.If medicines are to
be used safely, a well-functioning PV system is essential. Healthcare experts, regulatory authorities,
pharmaceutical businesses, and consumers will all benefit from it(3).With so many clinical trials and
other clinical research activities taking place in India, it's vital to understand the value of
pharmacovigilance and how it influences the life cycle of a product. DCGI has put in a lot of work to
create a reliable and effective pharmacovigilance system. However, more work and strategic planning
are required to meet the demands of a growing population while also ensuring that all data is recorded
and processed. To address the issues of inexperience and a lack of trained personnel, the DCGI might
take a step ahead and hire commercial firms to teach and set up an effective pharmacovigilance
system(22).
After considering the issues and obstacles that India has in developing an effective pharmacovigilance
system, the following suggestions may be made:
1. Establishing and maintaining an effective pharmacovigilance system.
2. Introducing PV inspections and making its reporting mandatory.
3. Discussions at a high level with a variety of stakeholders.
4. Expand the number of trained scientific and medical assessors in the Drug Control General of
India office for PV.
5. Creating a single adverse event reporting form that can be used by everyone in any country.
6. A clinical trial and post-marketing database for SAEs/SUSARs and ADRs is being built for signal
detection and access to all relevant data from different stakeholders.
7. Keep track of all new medications and indications in a standard database for each
pharmaceutical company.
8. Medical students, pharmacists, and nurses receive pharmacovigilance education and training.
9. Collaborating with pharmacovigilance groups to improve medication safety as information
technology advances, new potential for national and worldwide collaborations to improve
postmarking surveillance programmes and improve drug safety have emerged.
10. In India, establishing a network of pharmacovigilance and pharmacoepidemiologists(23).

CONCLUSION
The awareness of PV system regarding ADR reporting has increased in India. Various international
companies have been outsourcing PV system activities to India, which is fostering a positive PV
culture.Various universities of India have implemented the PV courses in the curriculum. The
government should work on raising pharmacist awareness and improving their expertise, as well as
providing them with facilities and power to conduct PV activities.A specific PV cell should be installed in

1563
Nat. Volatiles & Essent. Oils, 2021; 8(6): 1558-1565

every hospital to detect and report ADRs.In the near future, India will be the hub and outsourcing center
for global PV activity, due to population, talent, interest of healthcare providers, and present
development in the PV sector.

REFERENCES
1. Hans M, Gupta SK. Comparative evaluation of pharmacovigilance regulation of the United States,
United Kingdom, Canada, India and the need for global harmonized practices. Perspect Clin Res.
2018;9(4):170–4.
2. Wal P, Mehra R, Rizvi S, Vajpayee R. Pharmacovigilance: Need for Indian Pharma Industry. Int Res
J Pharm. 2015;6(11):740–3.
3. H. S, S. M. Pharmacovigilance system in India. Int J Pharm Sci Rev Res [Internet]. 2020;63(1):73–
80.
4. Hussain R, Hassali MA, Ur Rehman A, Muneswarao J, Hashmi F. Physicians’ understanding and
practices of pharmacovigilance: Qualitative experience from a lower middle-income country. Int J
Environ Res Public Health. 2020;17(7):1–15.
5. Rajgopal JKM, Shilpi K, Ak S. Pharmacovigilance : a review article. Innovare J Med Sci.
2016;4(4):6–7.
6. Bhumeshwar Sharma, Sourabh Kosey, Neelesh Kumar Mehra, Deepanshu Kumar Chitra RK.
Exploring Pharmacovigilance: A Narrative Review. J Harmon Res. 2015;4(2):201–12.
7. Mulkalwar S, Munjal N, Worlikar P, Behera L. Pharmacovigilance in India. Med J Dr DY Patil Univ.
2013;6(2):126.
8. Gohil KJ. Pharmacovigilance and Techniques : Focus 2020. WORLD J Pharm Pharm Sci.
2019;8(12):1296–320.
9. Fornasier G, Francescon S, Leone R, Baldo P. An historical overview over Pharmacovigilance. Int J
Clin Pharm 2018;40(4):744–7.
10. Caron J, Rochoy M, Gaboriau L, Gautier S. The history of pharmacovigilance. Therapie [Internet].
2016;71(2):129–34.
11. Khan Z, Muhammad K, Karatas Y, Bilen C, Khan FU, Khan FU. Pharmacovigilance and incidence of
adverse drug reactions in hospitalized pediatric patients: a mini systematic review. Egypt Pediatr
Assoc Gaz. 2020;68(1):1–7.
12. Aravindhswamy H, Sankar Narayanan R, Manigandan T, Aswath N, Hemalatha VT.
Pharmacovigilance, adverse drug reactions and future aspects of pharmacovigilance in India: A
review article. Indian J Public Heal Res Dev. 2019;10(12):1021–5.
13. Chauhan P, Yadav A, Kirodian B. Pharmacovigilance in Clinical Research: Past, Present and Future.
Int J Drug Regul Aff. 2016;4(4):1–6.
14. Jeetu G, Anusha G. Pharmacovigilance: A worldwide master key for drug safety monitoring. J
Young Pharm 2010;2(3):315–20.
15. Amale PN, SA D, YD N, NA A. Pharmacovigilance Process in India: An overview. J Pharmacovigil.
2018;06(02):1–7.
16. Kesharwani V, Farooqui MA, Kushwaha N, Singh RK, Jaiswal PK. An Overview on
Pharmacovigilance: a Key for Drug Safety and Monitoring. J Drug Deliv Ther. 2018;8(5):130–5.
17. Kumar A. Past, present and future of pharmacovigilance in India. Syst Rev Pharm. 2011;2(1):55–8.

1564
Nat. Volatiles & Essent. Oils, 2021; 8(6): 1558-1565

18. Sawarkar A, Sharma RK, Gautam V. Pharmacovigilance : Present status and future perspectives.
Pharma Innov. 2019;8(8):84–92.
19. Kalaiselvan V, Srivastava S, Singh A, Gupta S. Pharmacovigilance in India: Present Scenario and
Future Challenges. Drug Saf [Internet]. 2019;42(3):339–46. Available from:
https://doi.org/10.1007/s40264-018-0730-7
20. Jain S, Sharma R. Pharmacovigilance system and the future challenges in India-A Perspective . Int
J Pharm Res Technol. 2019;8(2):27–31.
21. Kumar S, Baldi A. Pharmacovigilance in India: Perspectives and Prospects. J Drug Deliv Ther.
2013;3(4):237–46.
22. Alves V. Pharmacovigilance in India : A Brief Review. Int J Adv Res Innov Ideas Educ.
2018;4(4):1295–7.
23. Duvvuru Ashok Kumar, Languluri Reddenna SAB. Pharmacovigilance Programme of India. Inov
Pharm. 2015;6(1):1–8.

1565